+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Urticaria Drugs Market 2018-2022 - Product Image

Global Urticaria Drugs Market 2018-2022

  • ID: 4755277
  • Report
  • Region: Global
  • 99 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • JDP Therapeutics
  • Meiji Holdings
  • Novartis
  • Taiho Pharmaceutical
  • MORE
Urticaria is a vastly prevalent disorder resulting in high medical consultations globally. The increase in risk factors for urticaria like latent infectious, chronic inflammatory diseases, auto-reactivity and alcohol consumption. Though the incident is increasing, and it is negatively impacting the quality of life of the people, most patients are undertreated due to challenges in affordability of drugs and low access to healthcare due to social stigma. The analysts have predicted that the urticaria drugs market will register a CAGR of over 10% by 2022.

Market Overview

Guidelines for management of urticaria patients

The management guidelines include clinical classification, etiology, investigations, diagnosis, treatment guidance along with special sections on children suffering from urticaria and the use of antihistamines in pregnant women or breastfeeding women.

High cost of urticaria management

The high medication costs along with the indirect costs are expected to put low-income patients at danger for suboptimal treatment and an increased burden due to poorly controlled disease.

For the detailed list of factors that will drive and challenge the growth of the urticaria drugs market during the 2018-2022, view this report.

Competitive Landscape

The global urticaria drugs market is moderately concentrated and the market being in a growth phase, the competition among companies is intense. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • JDP Therapeutics
  • Meiji Holdings
  • Novartis
  • Taiho Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Urticaria pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: BY TYPE OF DRUG
  • Segmentation by type of drug
  • Antihistamines
  • Anti-inflammatory agents
  • Sulfones
  • Biologics
PART 09: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
  • Comparison by application
  • Acute urticaria - Market size and forecast 2017-2022
  • Chronic urticaria - Market size and forecast 2017-2022
  • Market opportunity by application
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • EMEA - Market size and forecast 2017-2022
  • Americas - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Introduction of biologics for the treatment of urticaria
  • International guidelines for diagnosis and management of urticaria
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche (Genentech)
  • JDP Therapeutics
  • Meiji Holdings
  • Novartis
  • Taiho Pharmaceutical
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market

Exhibit 03: Market characteristics
Exhibit 04: Market segments

Exhibit 05: Pipeline drugs for urticaria

Exhibit 06: Market definition - Inclusions and exclusions checklist

Exhibit 07: Market size 2017

Exhibit 08: Validation techniques employed for market sizing 2017

Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)

Exhibit 10: Global - Year-over-year growth 2018-2022 (%)

Exhibit 11: Five forces analysis 2017

Exhibit 12: Five forces analysis 2022

Exhibit 13: Bargaining power of buyers

Exhibit 14: Bargaining power of suppliers

Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes

Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Application - Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Acute urticaria - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Acute urticaria - Year-over-year growth 2018-2022 (%)
Exhibit 23: Chronic urticaria - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Chronic urticaria - Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Customer landscape

Exhibit 27: Global - Market share by geography 2017-2022 (%) 57
Exhibit 28: Regional comparison 58
Exhibit 29: EMEA - Market size and forecast 2017-2022 ($ mn)

Exhibit 30: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in EMEA
Exhibit 32: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: F. Hoffmann-La Roche (Genentech) - Overview
Exhibit 45: F. Hoffmann-La Roche (Genentech) - Business segments
Exhibit 46: F. Hoffmann-La Roche (Genentech) - Organizational developments
Exhibit 47: F. Hoffmann-La Roche (Genentech) - Geographic focus
Exhibit 48: F. Hoffmann-La Roche (Genentech) - Segment focus
Exhibit 49: F. Hoffmann-La Roche (Genentech) - Key offerings
Exhibit 50: JDP Therapeutics - Overview

Exhibit 51: JDP Therapeutics - Business segments
Exhibit 52: JDP Therapeutics - Organizational developments
Exhibit 53: JDP Therapeutics - Key offerings
Exhibit 54: Meiji Holdings - Overview
Exhibit 55: Meiji Holdings - Organizational developments
Exhibit 56: Meiji Holdings - Key offerings
Exhibit 57: Novartis - Overview
Exhibit 58: Novartis - Business segments
Exhibit 59: Novartis - Organizational development
Exhibit 60: Novartis - Geographic focus
Exhibit 61: Novartis - Segment focus
Exhibit 62: Novartis - Key offerings
Exhibit 63: Taiho Pharmaceutical - Overview
Exhibit 64: Novartis - Organizational developments
Exhibit 65: Taiho pharmaceutical - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • JDP Therapeutics
  • Meiji Holdings
  • Novartis
  • Taiho Pharmaceutical
  • MORE
Global Urticaria Drugs Market 2018-2022

The analyst recognizes the following companies as the key players in the global urticaria drugs market: F. Hoffmann-La Roche (Genentech), JDP Therapeutics, Meiji Holdings, Novartis, Taiho Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the introduction of biologics for the treatment of urticaria.”

According to the report, one of the major drivers for this market is the guidelines for management of urticaria patients.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of urticaria management.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F. Hoffmann-La Roche (Genentech)
  • JDP Therapeutics
  • Meiji Holdings
  • Novartis
  • Taiho Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4755277
Adroll
adroll